Citius Pharmaceuticals, Inc. (CTXR)

Citius Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is October - September.

Year Ending	TTM	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019
Selling, General & Admin	15.85	15.3	11.75	9.84	8.09	6.29
Research & Development	12.88	14.82	17.66	12.24	8.81	8.6
Other Operating Expenses	10.39	6.62	3.91	1.45	0.8	0.72
Operating Expenses	39.11	36.73	33.32	23.53	17.71	15.6
Operating Income	-39.11	-36.73	-33.32	-23.53	-17.71	-15.6
Interest Expense / Income	0	0	0	0.01	0.02	0.02
Other Expense / Income	-3.49	-4.77	-0.25	-0.49	-0.18	-0.05
Pretax Income	-35.62	-31.97	-33.06	-23.05	-17.55	-15.56
Income Tax	0.58	0.58	0.58	0	0	0
Net Income	-36.2	-32.54	-33.64	-23.05	-17.55	-15.56
Preferred Dividends	1.15	1.15	0	1.45	0	0
Net Income Common	-37.35	-33.69	-33.64	-24.51	-17.55	-15.56
Shares Outstanding (Basic)	159	151	146	109	39	20
Shares Outstanding (Diluted)	159	151	146	109	39	20
Shares Change	8.77%	3.57%	34.52%	177.28%	94.25%	87.87%
EPS (Basic)	-0.24	-0.22	-0.23	-0.23	-0.45	-0.77
EPS (Diluted)	-0.24	-0.22	-0.23	-0.23	-0.45	-0.77
Free Cash Flow	-30.3	-29.06	-28.36	-24.26	-16.93	-12.44
Free Cash Flow Per Share	-0.19	-0.19	-0.19	-0.22	-0.43	-0.62
EBITDA	-35.42	-31.77	-32.88	-22.88	-17.38	-15.54
Depreciation & Amortization	0.2	0.19	0.18	0.16	0.15	0
EBIT	-35.62	-31.97	-33.06	-23.04	-17.53	-15.55

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).